Antimicrobial Surveillance Results in Significant Cost Saving

InPharma ◽  
1986 ◽  
Vol 563 (1) ◽  
pp. 4-5
Keyword(s):  
Cost Saving ◽  
Significant Cost Saving ◽  
Significant Cost ◽  
Antimicrobial Surveillance

Optimization Of Large Gas Cap Development Plan Though Pilot Learning Leading to Significant Cost Saving

2019 ◽  
Author(s):  
Pawan Agrawal ◽  
Osama Keshtta ◽  
Elyes Draoui
Keyword(s):  
Cost Saving ◽  
Development Plan ◽  
Significant Cost Saving ◽  
Significant Cost

Innovative tin electrolyte combining high technical standards with significant cost saving potentials

2012 ◽  
Author(s):  
Olaf Kurtz ◽  
Peter Kuhlkamp ◽  
Jurgen Barthelmes ◽  
Robert Ruther ◽  
Din-Ghee Neoh ◽  
...  
Keyword(s):  
Cost Saving ◽  
Significant Cost Saving ◽  
Significant Cost ◽  
Technical Standards

Tailored Innovative Bit Technologies Lead to Significant Cost Saving and Performance Improvement in the Ultra-Deep Formation of Tarim Basin in West China

2016 ◽  
Author(s):  
Xueqing Teng ◽  
Liang Zhao ◽  
Zhixiong Xu ◽  
Xiaomin Cheng ◽  
Ning Li ◽  
...  
Keyword(s):  
Cost Saving ◽  
Performance Improvement ◽  
Tarim Basin ◽  
Significant Cost Saving ◽  
Significant Cost ◽  
West China ◽  
And Performance

scholarly journals Are on-the-day group and save samples required for elective shoulder, hip and knee arthroplasties?

2018 ◽  
Vol 100 (8) ◽  
pp. 676-678
Author(s):  
L Hainsworth ◽  
J Tracy ◽  
C Spolton-Dean ◽  
O Donaldson
Keyword(s):  
Shoulder Arthroplasty ◽  
Surgical Techniques ◽  
Formal Group ◽  
Clinical Work ◽  
Work Load ◽  
Blood Transfusions ◽  
Significant Cost Saving ◽  
Blood Products ◽  
Single Centre ◽  
Significant Cost

Introduction Historically, patients undergoing an elective hip, knee or shoulder arthroplasty regularly required blood transfusions. Improved surgical techniques and perioperative optimisation have significantly decreased the requirement for blood transfusions. Currently, our patients have two group and save samples taken: one six weeks preoperatively and one on admission. This study aims to determine whether a second group and save is required prior to primary elective hip, knee or shoulder arthroplasty. Methods All cases of elective arthroplasty from a single centre were retrospectively analysed over a 16-month period. Each case was reviewed to determine those who had a group and save at preassessment, group and save at the time of the operation and the timing and number of blood products transfused. Results A total of 711 elective arthroplasty procedures were completed with 48 patients requiring a transfusion during their admission. 9.9% of hip arthroplasty patients, 3.8% of knee arthroplasty patients and 4.9% of shoulder arthroplasty patients required a transfusion. The majority of the transfusions occurred at least 24 hours postoperatively with 0.84% of patients requiring an intraoperative transfusion. Discussion The vast majority of transfusions were delivered more than 24 hours following the procedure, demonstrating that routinely cross-matched blood products are superfluous to requirements. It is our suggestion that a formal group and save be completed only if the need for a blood transfusion is formally established, leading to a significant cost saving, a reduction in clinical work load and patients having to undergo fewer procedures.

scholarly journals Valutazione clinica e metabolica dell’impiego dell’insulina Lispro in pazienti con diabete mellito scompensato

2005 ◽  
Vol 6 (4) ◽  
pp. 397-400
Author(s):  
Antonio Uneddu ◽  
Tito Antonio Paolini
Keyword(s):  
Cost Saving ◽  
Continuous Infusion ◽  
Preliminary Data ◽  
Cost Reduction ◽  
Insulin Analogue ◽  
Standard Of Care ◽  
Significant Cost ◽  
Diabete Mellito ◽  
Preliminary Results ◽  
Significant Cost Reduction

The aim of the present work is to report preliminary results about the administration of an insulin analogue, LisPro, to treat diabetic chetoacidosis. This new procedure, in respect to insulin continuous infusion, allow significant cost reduction in terms of medical and nurses time dedicated to the patient and hospitalization length. In our experience, LisPro treatment compared to the standard of care, has allowed hospital time reduction of 2,1 days per patient. This can be translated in cost saving of about 700,00 euro per case. These preliminary data, replicating the results coming from published international experiences, have to be confirmed in our country through the implementation of more representative studies

scholarly journals P089 The cost of repeat ANA testing in north west London pathology services

Rheumatology ◽  
2021 ◽  
Vol 60 (Supplement_1) ◽  
Author(s):  
Matthew Colquhoun ◽  
Maria Mouyis
Keyword(s):  
Imperial College ◽  
Musculoskeletal Symptoms ◽  
Freedom Of Information ◽  
Significant Cost Saving ◽  
Significant Cost ◽  
Total Cost ◽  
Average Data ◽  
North West ◽  
Information Request ◽  
The Cost

Abstract Background/Aims  The anti-nuclear antibody (ANA) test is commonly used to screen for autoimmune connective tissue (CTD) disease. It is a test that should be used judiciously and should only be requested if a patient presents with symptoms suggestive of a CTD and should not be used as a screening test for vague musculoskeletal symptoms. Recent studies have demonstrated that it is often repetitively requested in those patients both with a known positive and known negative ANA with little value in altering a diagnosis. With this information in mind, we sought to examine the frequency and associated cost of repeat ANA testing in hospital trusts served by North West London Pathology Services (NWL). Methods  The trusts included in the study were Imperial College Healthcare NHS Trust, Chelsea and Westminster Hospital Foundation Trust and Hillingdon Hospitals NHS Foundation Trust. Data was obtained regarding how many patients had repeat ANA testing in total between these trusts between 2017-2019. The data was obtained via a freedom of information request. Results  In total, there were 6,799 instances of repeated ANA testing in the same patient across three trusts over three years. This included one patient who had 16 ANA tests in a single year in 2017. The cost of an ANA test is £12.27. The total cost of repeat ANA testing in the three years across three trusts was £83,423.73 (£27,807.66 per year on average). Data is provided in tabular form and gives a breakdown of the number of repeat ANA tests per year and how many times the test was repeated in the same patient. Conclusion  The requesting of unnecessary tests can add to a hospital pathology workload and is associated with significant cost. It has been previously demonstrated in the literature that repeat ANA testing is of little value and rarely alters the diagnosis of a rheumatic disease. There is a large burden of repeated ANA testing in North West London Pathology Services and this is associated with significant expense. More judicious use of ANA testing can result in significant cost saving. This is the first study to specifically examine the cost of repeat ANA testing in the NHS. Disclosure  M. Colquhoun: Other; MC has received support to attend conferences from Pfizer. M. Mouyis: None.

Australia offshore well inventory characterisation and decommissioning cost saving opportunities through cap rock restoration and rigless/riserless techniques

2021 ◽  
Vol 61 (2) ◽  
pp. 445
Author(s):  
Christopher Murphy ◽  
Stuart A. Higgins
Keyword(s):  
Cost Saving ◽  
Federal Government ◽  
Cost Reduction ◽  
Oil And Gas ◽  
Economic Life ◽  
Third Party ◽  
Significant Cost ◽  
Cost Estimates ◽  
Resource Rent ◽  
Cap Rock

This research utilises the Geoscience Australia and NOPIMS public database to characterise the national inventory of active offshore oil and gas (O&G) wells and, through representative examples of dry and wet completions, establish the current well decommissioning cost opportunities associated with using riserless and rigless techniques to restore cap rock. These techniques have been successfully applied in the Gulf of Mexico (GoM) and this study explores the potential savings and barriers to adoption in the Australian offshore operating and regulatory context. Third party studies (Bills 2018; Wood Mackenzie 2020) have reported Australian O&G decommissioning cost estimates in the range of USD 33–49 billion over the next 30–40 years. The well decommissioning contribution to the total project cost has been estimated at 49% (OGUK 2020). This cost is materially significant to the economic life of the asset, the operator’s financial liability and a significant cost burden to the Federal Government through Petroleum Resource Rent Tax (PRRT) offsets. In this context there is a paucity of detail and transparency for well decommissioning cost estimates, to establish whether there are cost saving opportunities whilst still maintaining an acceptable level of risk both during plug and abandonment (P&A) operations and in the longer term when relinquished back to the Federal Government. This study illustrates how and to what extent the Australian offshore Federal well inventory could be decommissioned using cap rock restoration and rigless/riserless techniques and proposes a staged strategy to realise a progressive cost reduction of 21–41% over the base estimate of circa USD 4.08 billion benchmarked with OGUK (2019). This significant cost reduction aligns with the OGTC (2019) technology roadmap target of 35% supported in part by the pursuit of a rigless and riserless well decommissioning philosophy.

Cost-utility analysis on telemonitoring of users with pacemakers: The PONIENTE study

2018 ◽  
Vol 25 (4) ◽  
pp. 204-212 ◽  
Author(s):  
Antonio Lopez-Villegas ◽  
Daniel Catalan-Matamoros ◽  
Emilio Robles-Musso ◽  
Rafael Bautista-Mesa ◽  
Salvador Peiro
Keyword(s):  
Cost Saving ◽  
Cost Effective ◽  
Economic Assessment ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Significant Cost ◽  
Life Years ◽  
The Cost

Introduction Few studies have confirmed the cost-saving of telemonitoring of users with pacemakers (PMs). The purpose of this controlled, non-randomised, non-masked clinical trial was to perform an economic assessment of telemonitoring (TM) of users with PMs and check whether TM offers a cost-utility alternative to conventional follow-up in hospital. Methods Eighty-two patients implanted with an internet-based transmission PM were selected to receive either conventional follow-up in hospital ( n = 52) or TM ( n = 30) from their homes. The data were collected during 12 months while patients were being monitored. The economic assessment of the PONIENTE study was performed as per the perspectives of National Health Service (NHS) and patients. A cost-utility analysis was conducted to measure whether the TM of patients with PMs is cost-effective in terms of costs per gained quality-adjusted life years (QALYs). Results There was a significant cost-saving for participants in the TM group in comparison with the participants in the conventional follow-up group. From the NHS’s perspective, the patients in the TM group gained 0.09 QALYs more than the patients in the conventional follow-up group over 12 months, with a cost saving of 57.64% (€46.51 versus €109.79, respectively; p < 0.001) per participant per year. In-office visits were reduced by 52.49% in the TM group. The costs related to the patient perspective were lower in the TM group than in the conventional follow-up group (€31.82 versus €73.48, respectively; p < 0.005). The costs per QALY were 61.68% higher in the in-office monitoring group. Discussion The cost-utility analysis performed in the PONIENTE study showed that the TM of users with PMs appears to be a significant cost-effective alternative to conventional follow-up in hospital.

Sign in / Sign up

Export Citation Format

Share Document